Bcl-2 Heterodimer Antibody Detection for Cancer Treatment Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting cancer treatment sensitivity are hindered by difficulties in measuring consistent fluorescent signals for BH3 profiling and correlating protein levels with treatment efficacy, especially in solid tumors and fixed specimens, leading to a need for improved predictive testing.
Innovation Solution
Development of antibodies that specifically bind to Bcl-2 heterodimers, allowing for the detection of these heterodimers in solid tumor samples and determining a ratio to a reference value, which predicts patient sensitivity to cancer treatment, enabling tailored treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If functional BH3 measurement using JC-1 fluorescent dye is used to measure mitochondrial outer membrane permeabilization, then treatment sensitivity can be assessed, but measurement precision deteriorates due to difficulties in measuring consistent fluorescent signals
Solution Approach 1:
The patent replaces the functional fluorescent measurement system (JC-1 dye-based mitochondrial potential measurement) with a direct protein detection system using antibodies against Bcl-2 heterodimers. This substitution eliminates the need for complex functional assays and fluorescent signal measurement, directly addressing the inconsistency and reliability issues of the original method.
Solution Approach 2:
The patent introduces antibody-based detection as an intermediary between the biological target (Bcl-2 heterodimers) and the measurement system. Instead of measuring functional outcomes through fluorescent dyes, the antibodies serve as mediators to directly detect and quantify heterodimer presence, providing more consistent and reliable data.
2Quantity of substance
If direct measurement of protein levels of individual BH3-only proteins is used, then protein quantification is achieved, but measurement precision deteriorates because changes in protein levels are not consistently correlated with sensitivity to test anti-cancer agents
Solution Approach 1:
The patent merges the detection of multiple Bcl-2 family proteins into a unified heterodimer-based measurement system. Instead of measuring individual protein levels separately (which showed poor correlation with treatment sensitivity), the antibodies detect the functional heterodimer complexes, providing a more accurate predictor of treatment response.
Solution Approach 2:
The patent changes the measurement parameter from individual protein concentrations to heterodimer ratios. By measuring the ratio of heterodimer to monomer protein levels, the system captures the functional state of Bcl-2 family proteins more accurately, improving correlation with treatment sensitivity predictions.
3Adaptability or versatility
If combination of functional BH3 measurement with direct measurement of protein levels is used, then comprehensive profiling is achieved, but device complexity increases and becomes complicated and not suited for solid tumor or fixed specimens
Solution Approach 1:
The patent extracts the essential information needed for treatment sensitivity prediction from the complex combination of functional and protein level measurements. By focusing solely on heterodimer detection using specific antibodies, the system isolates the most predictive parameter while eliminating unnecessary complexity from multi-parameter assays.
Solution Approach 2:
The antibody-based heterodimer detection system provides universal applicability across different specimen types including solid tumors and fixed specimens. The same antibody-based approach can be applied to various sample types without requiring the complex, specimen-specific protocols needed for functional BH3 measurements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of these antibodies provides a predictive method for determining patient sensitivity to cancer treatments, allowing for adjusted dosing, treatment duration, or switching to different therapies based on heterodimer ratios, thereby improving treatment efficacy and patient outcomes.
Implementation Method 1
contacting a sample with an antibody or antibody format that recognizes a heterodimer comprising two B-cell lymphoma 2 (BCL-2) proteins
Data Source
AI summary
The present disclosure relates to compositions and methods of determining cancer cell sensitivity to treatment using antibodies that detect heterodimers comprising Bcl-2 proteins. The disclosure also provides methods for predicting a cancer patient's sensitivity to the cancer treatment.